NCT05338047: Phase 2: Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery ASCT
NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release
NCT04721002: Evaluate t(11;14) Status & BCL2 Expression in Adult Participants With MM (MEDICI)
The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): A Pooled Analysis of RRMM treated with IRd
NCT04754100: Phase 1 - AGENT-797 in Participants With Relapsed/Refractory Multiple Myeloma
Meta-Analysis of Ciltacabtagene Autoleucel Versus Physician’s Choice in the Treatment of RRMM
NCT04937777: EMN 23 - Study on the Management & Outcome of Systemic AL Amyloidosis in Europe
NCT04671251: Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma
NCT04436029: Phase 2: Descartes-11 Consolidation Treatment Patients With High-Risk Multiple Myeloma
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: phase III GMMG-MM5 trial
NCT04445701: Phase 1/2: Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dex RRMM
NCT04196491: Phase 1 - Evaluate the Safety of bb2121 in High Risk, New Myeloma (NDMM) (KarMMa-4)
The MAMMOTH study: Monoclonal Antibodies in Multiple Myeloma: Outcomes after Therapy Failure
NCT04136756: Phase 1 - NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
NCT03665155: Phase 1/2 - PET Imaging MM with 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Ab
NCT03489525: Phase 1: MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (MEDI2228)
NCT03448978: Phase 1/2 - Descartes-08 - anti-BCMA-CAR-mRNA-trans. auto CD8+ T cells in Myeloma
NCT03464916: Phase 1: Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in RRMM
Post-transplant consolidation plus lenalidomide maintenance vs lenalidomide maintenance alone